Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
StockNews.AI · 2 hours
AI Summary
Precision BioSciences presented ELIMINATE-B data showing PBGENE-HBV directly eliminates cccDNA in liver tissue, achieving a 1-log reduction with remaining cccDNA inactivated by indels. pgRNA loss occurred in all baseline-detectable patients and HBsAg declined across dose levels, supporting a potential finite HBV cure and a biomarker-driven path forward. Management highlighted a clear therapeutic window and manageable safety as data mature toward Part 2 expansion and nucleoside analog withdrawal strategies.
Sentiment Rationale
Significant early signals of cccDNA elimination and biomarker alignment could re-rate the HBV program; however, results are early-stage and single-program focused, so upside is contingent on replication and broader safety/efficacy confirmation.
Trading Thesis
DTIL could rally near-term on positive EASL data and clear biomarkers, with potential upside into year-end pending further trial updates.
Market-Moving
- PBGENE-HBV data bolster DTIL's leadership in cccDNA-targeting HBV therapies.
- Investor event and 2026 data updates may trigger near-term volatility.
- Safety signals appear manageable; no dose-limiting toxicities reported to date.
- Progress toward nucleoside analog withdrawal could influence pipeline valuation.
Key Facts
- PBGENE-HBV shows 1-log reduction in cccDNA transcripts in liver biopsies.
- <1% cccDNA remains; remaining edits permanently inactivate polymerase function.
- pgRNA loss observed in 100% of patients with baseline pgRNA detected.
- 100% HBsAg declines across all patients; safe profile across cohorts.
- Investor webcast today at 8 AM EDT; further updates expected by year-end 2026.
Companies Mentioned
- Precision BioSciences, Inc. (DTIL): Primary subject of the release; ELIMINATE-B data may serve as near-term catalyst.
- European Association for the Study of the Liver: Host of the EASL 2026 conference where data were presented; indirect price driver.
Industry News
Category: Industry News. The release reports a pivotal clinical data update from a biotech program, with potential strategic implications for DTIL's hepatitis B pursuit and investor sentiment around the ARCUS platform.